Dual SGLT1/2 inhibition with sotagliflozin improves cardiac function and metabolism in type 2 diabetic mice
Abstract
Sotagliflozin (SOTA), a dual sodium-glucose cotransporter (SGLT)1/2 inhibitor, improves cardiovascular outcomes in patients with diabetes and heart failure, yet the metabolic mechanisms underlying these benefits remain incompletely defined. As a model of type 2 diabetes, db/db mice were treated with SOTA (5 mg/kg/day) in drinking water for 4 weeks. Cardiac metabolism was assessed using LC-MS/MS, cardiac function by echocardiography, and susceptibility to ischemia/reperfusion injury in Langendorff-perfused hearts. Systemic metabolism was characterised by plasma biochemical profiling and 1H NMR spectroscopy of peripheral tissues. db/db mice exhibited obesity, hyperglycaemia, hyperinsulinaemia, and diastolic dysfunction, alongside perturbed cardiac and systemic metabolism. SOTA treatment improved hyperglycaemia, ventricular function and cardiac metabolomic profile without correcting obesity or insulin resistance. In the heart, SOTA partially restored glycolytic intermediates and improved bioenergetics, whereas systemic metabolic abnormalities largely persisted. These findings suggest dual SGLT1/2 inhibition induces selective cardiac metabolic remodelling in diabetic cardiomyopathy independent of global metabolic correction.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.